Alder BioPharmaceuticals, Inc.
Corporate Headquarters
11804 North Creek Parkway South
Bothell
Washington
98011
United States
Tel: 425-205-2900
Fax: 425-205-2901
Website: http://www.alderbio.com/
Email: hr@alderbio.com
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention.
Stock Symbol: ALDR
Stock Exchange: NASDAQ
119 articles about Alder BioPharmaceuticals, Inc.
-
Alder Biopharma Reports Second Quarter 2015 Financial And Operating Results
8/6/2015
-
Alder Biopharma To Host Conference Call To Discuss Second Quarter 2015 Financial And Operating Results
7/29/2015
-
Alder Biopharma Announces Exercise In Full Of Option To Purchase Additional Shares
7/1/2015
-
Alder Biopharma To Present At WBBA 2015 Life Science Innovation Northwest Conference
6/29/2015
-
Alder Biopharma Prices Public Offering Of Common Stock
6/26/2015
-
Alder Biopharma Announces Commencement Of Public Offering Of Common Stock
6/25/2015
-
Alder Biopharma To Present At Jefferies and Co. 2015 Global Healthcare Conference
5/28/2015
-
HR Exec Says Alder Biopharma Will Grow 30% in 2015, As Hunt for Candidates Continues
5/15/2015
-
Alder Biopharma Presents Positive Clinical Data For ALD403 At The 17th Congress Of The International Headache Society
5/15/2015
-
Alder Biopharma Reports First Quarter 2015 Financial And Operating Results
5/8/2015
-
Alder Biopharma Announces Presentations At 17th Congress Of The International Headache Society On Data From ALD403 Clinical Trials
5/6/2015
-
Alder Biopharma Release: Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Rheumatoid Arthritis, Meets Primary Endpoint In Follow-On Phase IIb Clinical Trial
5/5/2015
-
Alder Biopharma To Host Conference Call To Discuss First Quarter 2015 Financial And Operating Results
4/30/2015
-
Alder Biopharma to Ramp Up Hiring for Migraine Phase III Trials
4/15/2015
-
Alder Biopharmaceuticals Inc. Reports Fourth Quarter And Year-End 2014 Financial And Operating Results
3/5/2015
-
Alder Biopharmaceuticals Inc. To Host Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial And Operating Results
2/25/2015
-
Alder Biopharmaceuticals Inc. To Present At 2015 Leerink Global Healthcare Conference
2/5/2015
-
Alder Biopharmaceuticals Inc. Announces Exercise In Full Of Option To Purchase Additional Shares
1/23/2015
-
Alder Biopharmaceuticals Inc. Announces Pricing Of Follow-On Offering
1/8/2015
-
Alder Biopharmaceuticals Inc. Announces Commencement Of Follow-On Offering
1/6/2015